Huperzine for Cognitive and Functional Impairment in Schizophrenia
Conditions
Schizophrenia
What is the purpose of this trial?
Huperzine is a natural plant product with procognitive properties in patients with Alzheimer's disease. Cognitive difficulties hamper functioning in schizophrenia as well. The present study will investigate whether huperzine improves cognition and functioning in patients with schizophrenia.
Participation Guidelines
- Age:
- 18 Years - 55 Years
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Biomedisyn Corporation
Yale University - Dates:
- March 2010
- Last Updated:
- February 28, 2013
- Study HIC#:
- 0707002913
Clinicaltrials.gov ID: NCT00963846
